SS-31 and elamipretide are linked in literature, but a research chemical is not automatically equivalent to a regulated finished drug product or branded formulation.
What procurement and laboratory teams should review
State sequence, salt form and analyte identity
Separate research COA evidence from drug-product controls
Do not use brand claims for third-party material
Check whether cited studies are preclinical or clinical
Verify the scope behind every compliance term
COA, GMP, DMF, LOA, audit and quality agreement describe different evidence or responsibilities. Their relevance depends on the product, manufacturing stage, jurisdiction and buyer’s intended research or development pathway.
- Ask which legal entity, site, material and operation a claim covers.
- Verify confidential-file reference procedures separately from product release.
- Document outsourced roles, change notification and destination responsibilities.
Questions to resolve before quotation or release
- Is this research material or a regulated product?
- Which sequence and salt form are supplied?
- Does evidence apply to the same formulation?
SS-31 listings are for laboratory research and not represented as prescription products.
Source material and further reading
This guide is informed by the following primary guidance and established technical resources. Always confirm the current version and its applicability to your material and jurisdiction.
HK PEPTIDES materials are supplied for laboratory research and documentation workflows only. They are not intended for human consumption, diagnostic use, therapeutic use, veterinary use or clinical application.